This is a working overview of 研究代号, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
=== Physiological roles in organs and tissues === FcRn is expressed on antigen-presenting leukocytes such as dendritic cells and is also expressed in neutrophils to help clear opsonized bacteria. In the kidneys, FcRn is expressed on epithelial cells called podocytes to prevent IgG and albumin from clogging the glomerular filtration barrier. Current studies are investigating FcRn in the liver because there are relatively low concentrations of both IgG and albumin in liver bile despite high concentrations in the blood. Studies have also shown that FcRn-mediated transcytosis is involved with the trafficking of the HIV-1 virus across genital tract epithelium.
== Types == All human rabies vaccines are inactivated vaccines made by inactivation of virus-containing material. The oldest kind are nerve tissue vaccines, made from the nerve tissue of rabies-infected animals. They are still approved in a few countries. They are not recommended by the WHO as they are less effective and have greater side effects. They also contain impurities of nervous origin such as myelin. Instead, WHO recommends Cell Culture Vaccines and Embryonated egg-based vaccines (CCEEV), where the virus is grown in cultured cells or fertilized duck eggs before being inactivated. The virus is then separated out and used for making the vaccine by ultrafiltration or ultracentrifugation. The process renders CCEEVs purer and more concentrated, which contributes to its safety and effectiveness. As with the older type, CCEEVs can be used in both pre- and post-exposure vaccinations. Specific CCEEVs are classified by the type of cell the virus is grown in and include:
=== Anisotropy of the interface kinetics === Even if the temperature gradient within the slurry is perfectly vertical, it is common to see tilting or curvature of the lamellae as they grow through the suspension. To explain this, it is possible to define two distinct growth directions for each ice crystal. There is the direction determined by the temperature gradient, and the one defined by the preferred growth direction crystallographically speaking. These angles are often at odds with one another, and their balance will describe the tilt of the crystal. The non-overlapping growth directions also help to explain why dendritic textures are often seen in freeze-casts. This texturing is usually found only on the side of each lamella; the direction of the imposed temperature gradient. The ceramic structure left behind shows the negative image of these dendrites. In 2013, Deville et al. made the observation that the periodicity of these dendrites (tip-to-tip distance) actually seems to be related to the primary crystal thickness.
However, a 2015 estimate that used a new method for calibrating molecular clocks confirmed that while modern birds originated early in the Late Cretaceous, likely in Western Gondwana, a pulse of diversification in all major groups occurred around the Cretaceous–Palaeogene extinction event. Modern birds would have expanded from West Gondwana through two routes. One route was an Antarctic interchange in the Paleogene. The other route was probably via Paleocene land bridges between South America and North America, which allowed for the rapid expansion and diversification of Neornithes into the Holarctic and Paleotropics. On the other hand, the occurrence of Asteriornis in the Northern Hemisphere suggest that Neornithes dispersed out of East Gondwana before the Paleocene.
Sources: en.wikipedia.org
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum). OHPH is given by injection into muscle at regular intervals. OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). OHPH was first described by 1954 and was introduced for medical use by 1957. It has been used clinically in France and Monaco in the past but is no longer marketed.
Authorities in Italy have investigated a 'Ndrangheta mafia clan accused of trafficking and illegally dumping nuclear waste. According to a whistleblower, a manager of the Italy state energy research agency Enea paid the clan to get rid of 600 drums of toxic and radioactive waste from Italy, Switzerland, France, Germany, and the United States, with Somalia as the destination, where the waste was buried after buying off local politicians. Former employees of Enea are suspected of paying the criminals to take waste off their hands in the 1980s and 1990s. Shipments to Somalia continued into the 1990s, while the 'Ndrangheta clan also blew up shiploads of waste, including radioactive hospital waste, sending them to the sea bed off the Calabrian coast. According to the environmental group Legambiente, former members of the 'Ndrangheta have said that they were paid to sink ships with radioactive material for the last 20 years. In 2008, Afghan authorities accused Pakistan of illegally dumping nuclear waste in the southern parts of Afghanistan when the Taliban were in power between 1996 and 2001. The Pakistani government denied the allegation.
Lente insulin (derived from the Italian word lento, meaning "slow"), also known as insulin zinc suspension, was an intermediate-acting insulin that is no longer used in humans. Its effects begin one to two hours after administration, with peak activity occurring approximately 8 to 12 hours post-injection, and some residual effects lasting beyond 24 hours. Manufacturers discontinued Lente insulin and other similar insulin analogs in the mid-2000s, and it is no longer approved for human use in the United States. This decision was partly due to the medical community's preference for more predictable insulin formulations, such as recombinant NPH insulin. Similarly to the modern brands of NPH and regular insulin, which are still sold, lente insulins would be marketed under the name of the rest of the insulins in a brand's product line, followed by the letter L.
== Enthalpy change == The enthalpy of sublimation has commonly been predicted using the equipartition theorem. If the lattice energy is assumed to be approximately half the packing energy, then the following thermodynamic corrections can be applied to predict the enthalpy of sublimation. Assuming a 1 molar ideal gas gives a correction for the thermodynamic environment (pressure and volume) in which pV = RT, hence a correction of 1RT. Additional corrections for the vibrations, rotations and translation then need to be applied. From the equipartition theorem gaseous rotation and translation contribute 1.5RT each to the final state, therefore a +3RT correction. Crystalline vibrations and rotations contribute 3RT each to the initial state, hence −6RT. Summing the RT corrections; −6RT + 3RT + RT = −2RT. This leads to the following approximate sublimation enthalpy. A similar approximation can be found for the entropy term if rigid bodies are assumed.
=== Nephrogenesis === One example of this, the most well described of the developmental METs, is kidney ontogenesis. The mammalian kidney is primarily formed by two early structures: the ureteric bud and the nephrogenic mesenchyme, which form the collecting duct and nephrons respectively (see kidney development for more details). During kidney ontogenesis, a reciprocal induction of the ureteric bud epithelium and nephrogenic mesenchyme occurs. As the ureteric bud grows out of the Wolffian duct, the nephrogenic mesenchyme induces the ureteric bud to branch. Concurrently, the ureteric bud induces the nephrogenic mesenchyme to condense around the bud and undergo MET to form the renal epithelium, which ultimately forms the nephron. Growth factors, integrins, cell adhesion molecules, and protooncogenes, such as c-ret, c-ros, and c-met, mediate the reciprocal induction in metanephrons and consequent MET.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。